China’s Ascepion Out-licenses Cancer Drug Candidate to Debiopharm

Did you know?

ChinaBio^® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…

More white papers:

>>China Partnering 2012: Driving Future Innovation

>>China Life Science 2012: From Local to Global

Free Content

Week in Review

In My Opinion

Free Articles

Education Center

Interfax-BW Releases

Subscriber Content

China’s Ascepion Out-licenses Cancer Drug Candidate to Debiopharm

publication date: Jun 18, 2012

Ascepion Pharma of Suzhou has out-licensed worldwide rights to one of its small molecule drug candidates to Debiopharm Group™ of Switzerland. The molecule, ASP-08126, is a multikinase inhibitor currently in pre-clinical development. ASP-08126 is an oral drug that binds and inhibits several tyrosine kinase oncogenes. These oncogenes are implicated in various parts of cancer development including tumor growth, metastasis and angiogenesis. Terms of the agreement were not disclosed. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Click here to join.